Combined Immunotherapy and Chemotherapy for Muscle-invasive Bladder Cancer

COVID-19 update:

In response to the COVID pandemic, Scripps Health has either temporarily suspended or limited enrollment with appropriate precautions for all clinical trials. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
IRB-19-7391
Munveer S Bhangoo, MD
This study will test the effectiveness of Pembrolizumab (KEYTRUDA) given before and after surgery for the treatment of muscle-invasive bladder cancer. Pembrolizumab is used as an immune-enhancing medication, that may block immune pathways for tumor growth.

Inclusion Criteria

  • Be 18 years of age or older
  • Have a confirmed diagnosis of Muscle – invasive Bladder Cancer (MIBC), Clinical Stage T2-T4aN0M0
  • Must be eligible to receive cisplatin chemotherapy.
  • Be eligible for surgical treatment and agree to planned surgical treatment

Exclusion Criteria

  • Have received any prior systemic anti-cancer treatment for MIBC
  • Be pregnant or breastfeeding or expecting to conceive or father children within the defined study duration
  • Have a known history of HIV, Hepatitis B, or active Hepatitis C

Additional Info

  • All patients will receive chemotherapy (cisplatin + gemcitabine) and surgery and will be randomly selected to receive either pembrolizumab or placebo.
  • All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines. Study treatment will occur for approximately 1 year and patients will be followed for up to 5 years after treatment has ended.
  • For more information, search for NCT03924856 at www.clinicaltrials.gov

Contact Info: